- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03096405
Impact MRSA -PCR on Patient Management
Staphylococcus aureus represents one of the most met germs, with Escherichia coli, during bacteremia. Microbiologist distinguish at aureus S. two profiles of resistance in beta-lactamines: S. aureus sensitive to the methicillin ( SASM) and the S. aureus resistant to the methicillin ( SARM).
With the implementation of the MALDI-TOF, it is now possible to identify the origin responsible of the bacteremia the day of the positivity of the hemoculture ( J0) and to set up a treatment with adapted antibiotic, which, in the case of a sepsis to aureus S., is the vancomycine. Ye it was demonstrated, that the use of the vancomycine on the SASM increased the average duration of stay and a more important rate of relapse.
The PCR SARM was organized in the GHPSJ in 2014. It allows from the day of the positivity of the hemoculture ( J0), to determine the phenotype of resistance of S. aureus.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Ile-de-France
-
Paris, Ile-de-France, France, 75014
- Groupe hospitalier Paris Saint Joseph
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Hemoculture positive to Staphylococcus Aureus Methicillin Sensitive
Exclusion Criteria:
- Positive test to Staphylococcus Aureus Methicillin Sensitive but not hospitalized.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Adaptation duration of antibiotherapy
Time Frame: 24 hours
|
24 hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mortality
Time Frame: Day 30
|
Day 30
|
average duration of hospitalization
Time Frame: day 30
|
day 30
|
Collaborators and Investigators
Investigators
- Principal Investigator: MIZRAHI Assaf, MD, Groupe Hospitalier Paris St Joseph
- Study Chair: LEMONNIER Alban, MD, Groupe Hospitalier Paris St Joseph
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PCR-SARM
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on MRSA Bacteremia
-
LegoChem Biosciences, IncRecruitingMRSA BacteremiaKorea, Republic of
-
Hunter Holmes Mcguire Veteran Affairs Medical CenterCenters for Disease Control and Prevention; Sage Products, Inc.UnknownMRSA Infection | MRSA Colonization | VRE Infection | VRE Colonization | Nosocomial BacteremiaUnited States
-
Vanderbilt University Medical CenterRecruitingBloodstream Infection | Vancomycin | MRSA Bacteremia | Sepsis BacterialUnited States
-
Hunter Holmes Mcguire Veteran Affairs Medical CenterJohns Hopkins University; Washington University School of Medicine; Weill Medical... and other collaboratorsCompletedMRSA Infection | MRSA Colonization | VRE Infection | VRE Colonization | Nosocomial Bacteremia | Nosocomial FungemiaUnited States
-
ContraFectNo longer availableCovid19 | MRSA Bacteremia | MRSA Bloodstream Infection | MRSA Right-sided EndocarditisUnited States
-
Forest LaboratoriesCompletedStaphylococcus Aureus Bacteremia | Methicillin-resistant Staphylococcus Aureus (MRSA) BacteremiaUnited States
-
Hvidovre University HospitalRecruiting
-
Children's Hospital of PhiladelphiaJohns Hopkins University; University of Pennsylvania; Centers for Disease Control... and other collaboratorsRecruitingSepsis | Septic Shock | Sepsis, Severe | Sepsis Bacteremia | Sepsis Mrsa | Antimicrobial - Induced Nephropathy | Septic SyndromeUnited States
-
Indiana UniversityWithdrawnHospital Acquired MRSA | Community Acquired MRSAUnited States
Clinical Trials on Polymerase Chain Reaction of Methicillin Resistant Staphyloccus Aureus
-
Assistance Publique Hopitaux De MarseilleTerminatedSystemic Lupus Erythematosus (SLE)France
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Assiut UniversityUnknown
-
Nanjing First Hospital, Nanjing Medical UniversityZhongda HospitalRecruitingStroke, Ischemic | Stroke, Acute | Endovascular TreatmentChina
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingIschemic Stroke | Acute StrokeChina
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)Completed
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
University of California, San FranciscoNational Cancer Institute (NCI)Completed
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)Withdrawn
-
Boston Medical CenterRecruitingMultiple MyelomaUnited States